PT4545100T - Soluções estáveis e concentradas de complexos de radionuclídeos - Google Patents

Soluções estáveis e concentradas de complexos de radionuclídeos

Info

Publication number
PT4545100T
PT4545100T PT251623948T PT25162394T PT4545100T PT 4545100 T PT4545100 T PT 4545100T PT 251623948 T PT251623948 T PT 251623948T PT 25162394 T PT25162394 T PT 25162394T PT 4545100 T PT4545100 T PT 4545100T
Authority
PT
Portugal
Prior art keywords
stable
concentrated solutions
radionuclide complexes
radionuclide
complexes
Prior art date
Application number
PT251623948T
Other languages
English (en)
Original Assignee
Advanced Accelerator Applications S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT4545100(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Application filed by Advanced Accelerator Applications S A filed Critical Advanced Accelerator Applications S A
Publication of PT4545100T publication Critical patent/PT4545100T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PT251623948T 2018-07-25 2018-09-25 Soluções estáveis e concentradas de complexos de radionuclídeos PT4545100T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions

Publications (1)

Publication Number Publication Date
PT4545100T true PT4545100T (pt) 2026-02-16

Family

ID=63794577

Family Applications (7)

Application Number Title Priority Date Filing Date
PT251624037T PT4541381T (pt) 2018-07-25 2018-09-25 Soluções estáveis e concentradas de complexos de radionuclídeos
PT251623963T PT4545101T (pt) 2018-07-25 2018-09-25 Soluções estáveis e concentradas de complexos de radionuclídeos
PT187831367T PT3826686T (pt) 2018-07-25 2018-09-25 Soluções estáveis de complexo de radionuclídeo concentrado
PT251623948T PT4545100T (pt) 2018-07-25 2018-09-25 Soluções estáveis e concentradas de complexos de radionuclídeos
PT252008263T PT4640241T (pt) 2018-07-25 2018-09-25 Solues estveis e concentradas de complexos de radionucldeos
PT251623906T PT4541379T (pt) 2018-07-25 2018-09-25 Soluções de complexos radionuclídicos estáveis e concentradas
PT251623914T PT4541380T (pt) 2018-07-25 2018-09-25 Soluções estáveis e concentradas de complexos de radionuclídeos

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PT251624037T PT4541381T (pt) 2018-07-25 2018-09-25 Soluções estáveis e concentradas de complexos de radionuclídeos
PT251623963T PT4545101T (pt) 2018-07-25 2018-09-25 Soluções estáveis e concentradas de complexos de radionuclídeos
PT187831367T PT3826686T (pt) 2018-07-25 2018-09-25 Soluções estáveis de complexo de radionuclídeo concentrado

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT252008263T PT4640241T (pt) 2018-07-25 2018-09-25 Solues estveis e concentradas de complexos de radionucldeos
PT251623906T PT4541379T (pt) 2018-07-25 2018-09-25 Soluções de complexos radionuclídicos estáveis e concentradas
PT251623914T PT4541380T (pt) 2018-07-25 2018-09-25 Soluções estáveis e concentradas de complexos de radionuclídeos

Country Status (23)

Country Link
EP (7) EP4545100B1 (pt)
JP (3) JP7402218B2 (pt)
KR (4) KR102865113B1 (pt)
CN (5) CN112584875A (pt)
AU (7) AU2018433575B2 (pt)
BR (1) BR112021001148A2 (pt)
CA (1) CA3153630A1 (pt)
CO (1) CO2021000506A2 (pt)
DE (3) DE202018007006U1 (pt)
DK (7) DK4640241T3 (pt)
ES (6) ES3064434T3 (pt)
FI (7) FI4545101T3 (pt)
HR (6) HRP20260222T1 (pt)
HU (1) HUE072720T2 (pt)
IL (5) IL280314B1 (pt)
LT (7) LT4541381T (pt)
MX (2) MX2021000805A (pt)
PL (6) PL4545100T3 (pt)
PT (7) PT4541381T (pt)
RS (7) RS67729B1 (pt)
SG (1) SG11202100645XA (pt)
SI (6) SI4541381T1 (pt)
WO (1) WO2020021322A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
US20250032652A1 (en) * 2021-11-30 2025-01-30 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CA3235923A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
US20260102526A1 (en) * 2024-06-27 2026-04-16 Curium Us Llc 177lutetium-dota-tate formulations
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
WO2018081860A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Also Published As

Publication number Publication date
FI4541381T3 (fi) 2026-04-01
PL4541380T3 (pl) 2026-03-30
AU2022203683B2 (en) 2023-12-21
LT4541379T (lt) 2026-02-10
RS67667B1 (sr) 2026-02-27
ES3065583T3 (en) 2026-05-06
DK4545100T3 (da) 2026-02-23
EP4541380A3 (en) 2025-07-23
RS67755B1 (sr) 2026-03-31
EP4545100B1 (en) 2025-12-10
ES3064434T3 (en) 2026-04-24
ES3064589T3 (en) 2026-04-27
AU2025220852A1 (en) 2025-09-11
DK4545101T3 (da) 2026-03-02
IL280314A (en) 2021-03-25
DE202018007007U1 (de) 2025-11-13
KR20210035855A (ko) 2021-04-01
FI3826686T3 (fi) 2025-08-20
AU2026204487A1 (en) 2026-07-02
AU2025220852B2 (en) 2025-10-23
EP4541379B1 (en) 2025-11-19
WO2020021322A1 (en) 2020-01-30
CN121081692A (zh) 2025-12-09
EP4545101B1 (en) 2025-12-10
DK4541379T3 (da) 2026-02-02
IL319542A (en) 2025-05-01
IL326944A (en) 2026-05-01
LT4545101T (lt) 2026-03-10
RS68308B1 (en) 2026-07-31
JP2025111424A (ja) 2025-07-30
PT4640241T (pt) 2026-07-17
LT3826686T (lt) 2025-08-25
RS67754B1 (sr) 2026-03-31
FI4545101T3 (fi) 2026-02-24
MX2021000805A (es) 2021-05-12
HRP20260237T1 (hr) 2026-04-10
DK3826686T3 (da) 2025-08-25
EP4640241B1 (en) 2026-06-03
HRP20260179T1 (hr) 2026-04-10
EP4541380A2 (en) 2025-04-23
ES3067415T3 (en) 2026-05-21
CN120860272A (zh) 2025-10-31
EP4640241A2 (en) 2025-10-29
AU2022203683A1 (en) 2022-06-16
LT4541381T (lt) 2026-03-25
PT3826686T (pt) 2025-08-04
IL319542B2 (en) 2026-08-01
EP4545100A2 (en) 2025-04-30
PL4541379T3 (pl) 2026-03-23
DK4541381T3 (da) 2026-04-07
SG11202100645XA (en) 2021-02-25
KR102865113B1 (ko) 2025-09-26
DE202018007006U1 (de) 2025-11-13
FI4541379T3 (fi) 2026-02-17
JP2023117417A (ja) 2023-08-23
SI4541380T1 (sl) 2026-04-30
IL319542B1 (en) 2026-04-01
BR112021001148A2 (pt) 2021-04-20
EP3826686B1 (en) 2025-05-21
HRP20260338T1 (hr) 2026-04-10
EP4541379A2 (en) 2025-04-23
CN120860270A (zh) 2025-10-31
IL319541B1 (en) 2025-09-01
PL4541381T3 (pl) 2026-05-11
SI4545101T1 (sl) 2026-04-30
IL280314B1 (en) 2026-07-01
JP2022501313A (ja) 2022-01-06
KR20250017751A (ko) 2025-02-04
KR102932818B1 (ko) 2026-03-03
SI4541379T1 (sl) 2026-03-31
EP4640241A3 (en) 2025-12-10
AU2025204901A1 (en) 2025-07-17
AU2025202231B2 (en) 2026-05-14
MX2025012060A (es) 2025-11-03
CO2021000506A2 (es) 2021-04-19
FI4541380T3 (fi) 2026-03-02
PL3826686T3 (pl) 2025-09-22
ES3038413T3 (en) 2025-10-13
EP4541380B1 (en) 2025-12-10
EP4541381A3 (en) 2025-07-23
KR20240033296A (ko) 2024-03-12
PT4541381T (pt) 2026-03-17
EP4541379A3 (en) 2025-07-23
KR102643582B1 (ko) 2024-03-05
EP4541381B1 (en) 2026-02-04
IL313560A (en) 2024-08-01
DK4640241T3 (da) 2026-07-27
IL319541A (en) 2025-05-01
AU2024201217B2 (en) 2025-02-27
FI4640241T3 (fi) 2026-07-21
HRP20250912T1 (hr) 2025-09-26
PT4545101T (pt) 2026-02-24
IL319541B2 (en) 2026-01-01
PT4541380T (pt) 2026-02-24
HUE072720T2 (hu) 2025-12-28
AU2018433575B2 (en) 2022-07-07
CA3153630A1 (en) 2020-01-30
AU2025202231A1 (en) 2025-04-17
EP4541381A2 (en) 2025-04-23
SI3826686T1 (sl) 2025-09-30
EP4545101A3 (en) 2025-07-23
IL313560B1 (en) 2025-07-01
AU2024201217A1 (en) 2024-03-14
CN120860271A (zh) 2025-10-31
PL4545101T3 (pl) 2026-03-30
AU2018433575A1 (en) 2021-02-11
EP3826686A1 (en) 2021-06-02
EP4545100A3 (en) 2025-07-23
HRP20260100T1 (hr) 2026-04-10
LT4640241T (lt) 2026-07-27
DK4541380T3 (da) 2026-02-23
HRP20260222T1 (hr) 2026-03-27
LT4545100T (lt) 2026-02-25
DE202018006567U1 (de) 2021-04-01
CN112584875A (zh) 2021-03-30
PT4541379T (pt) 2026-01-29
PL4545100T3 (pl) 2026-03-30
KR20260030955A (ko) 2026-03-06
FI4545100T3 (fi) 2026-03-02
SI4541381T1 (sl) 2026-05-29
JP7796696B2 (ja) 2026-01-09
RS67729B1 (sr) 2026-03-31
LT4541380T (lt) 2026-03-10
EP4545101A2 (en) 2025-04-30
JP7402218B2 (ja) 2023-12-20
IL313560B2 (en) 2025-11-01
RS67864B1 (sr) 2026-04-30
SI4545100T1 (sl) 2026-03-31
AU2025204901B2 (en) 2025-09-18
RS67034B1 (sr) 2025-08-29
ES3063402T3 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
PT4545101T (pt) Soluções estáveis e concentradas de complexos de radionuclídeos
EP3793613C0 (en) IMMUNOCONJUGATES
MA45225A (fr) Complexes radiopharmaceutiques
PL3672948T3 (pl) Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
DK3651736T3 (da) Langtidsvirkende formuleringer
DK3672967T3 (da) Azaindolylpyridon- og diazaindolylpyridonforbindelser
EP3463235A4 (en) ANTISEPTIC SOLUTIONS AND APPLICATORS
PL3820609T3 (pl) Zastosowanie n-chelatujących kompleksów rutenu w reakcji metatezy
IL265037B (en) Imide compound and use thereof
EP3628314A4 (en) ANTI-INFLAMMATORY AGENT
IT201700120375A1 (it) Soluzioni acquose stabili che comprendono PUFAs
DK3515492T3 (da) Midler mod cancer og fremstilling heraf
UA39320S (uk) Тачка будівельна
UA39321S (uk) Тачка будівельна
UA39313S (uk) Тачка будівельна
UA39506S (uk) Тачка будівельна
UA39447S (uk) Тачка будівельна
UA39314S (uk) Тачка будівельна
UA39339S (uk) Тачка будівельна
UA39338S (uk) Тачка будівельна
UA39322S (uk) Тачка будівельна
UA39318S (uk) Тачка будівельна
UA39316S (uk) Тачка будівельна
ES1218861Y (es) Pieza de joyería
TH190847S (th) ต่างหู